CTLT - Catalent, Inc.

NYSE - NYSE Delayed Price. Currency in USD
35.21
+0.58 (+1.67%)
At close: 4:05PM EST
Stock chart is not supported by your current browser
Previous Close34.63
Open34.54
Bid0.00 x 1800
Ask0.00 x 1000
Day's Range34.32 - 35.35
52 Week Range29.23 - 47.87
Volume1,332,780
Avg. Volume1,062,209
Market Cap5.119B
Beta (3Y Monthly)1.73
PE Ratio (TTM)73.05
EPS (TTM)0.48
Earnings DateFeb 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.92
Trade prices are not sourced from all markets
  • Markit3 days ago

    See what the IHS Markit Score report has to say about Catalent Inc.

    # Catalent Inc ### NYSE:CTLT View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for CTLT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CTLT. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $6.41 billion over the last one-month into ETFs that hold CTLT are among the highest of the last year, but the rate of growth is slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire3 days ago

    Catalent, Inc. Announces Second Quarter Fiscal Year 2019 Earnings Conference Webcast

    Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2019 ended December 31, 2018, before the market open on Tuesday, February 5, 2019. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.

  • Associated Press10 days ago

    Catalent to expand Wisconsin biomanufacturing operation

    MADISON, Wis. (AP) — A global biotechnology company plans to add more than 100 new jobs at its facility in southern Wisconsin.

  • Business Wire11 days ago

    Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.

  • Stocks down in December for pharma firms in the Triangle
    American City Business Journals22 days ago

    Stocks down in December for pharma firms in the Triangle

    Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.

  • Business Wire29 days ago

    Catalent, Inc. to Present at the 37th Annual J.P. Morgan Health Care Conference

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that John Chiminski, Chairman & Chief Executive Officer, will present at the 37th Annual J.P.

  • Is Catalent Inc (CTLT) A Good Stock To Buy?
    Insider Monkeylast month

    Is Catalent Inc (CTLT) A Good Stock To Buy?

    Is Catalent Inc (NYSE:CTLT) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]

  • Moving Average Crossover Alert: Catalent
    Zackslast month

    Moving Average Crossover Alert: Catalent

    Catalent, Inc. (CTLT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
    PR Newswire2 months ago

    Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine

    NEW HAVEN, Conn., Dec. 3, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) today announced positive topline results from a randomized, controlled Phase 3 clinical trial (BHV3000-303 or Study 303) evaluating the efficacy and safety of its Zydis® orally dissolving tablet (ODT) formulation of rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine. In Study 303, rimegepant Zydis ODT statistically differentiated from placebo on the two co-primary endpoints as well as the first 21 consecutive primary and secondary outcome measures that were prespecified in hierarchical testing.

  • Zacks2 months ago

    Stocks Hold Onto Gains Ahead of Powell Speech

    Stocks Hold Onto Gains Ahead of Powell Speech

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CTLT earnings conference call or presentation 6-Nov-18 1:15pm GMT

    Q1 2019 Catalent Inc Earnings Call

  • See what the IHS Markit Score report has to say about Catalent Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Catalent Inc.

    Short interest is extremely low for CTLT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CTLT. ETFs that hold CTLT had net inflows of $444 million over the last one-month.

  • Simply Wall St.2 months ago

    What Does Catalent Inc’s (NYSE:CTLT) P/E Ratio Tell You?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how Catalent Inc’s (NYSE:CTLT) P/E Read More...

  • Catalent Inc (CTLT) Q1 2019 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Catalent Inc (CTLT) Q1 2019 Earnings Conference Call Transcript

    CTLT earnings call for the period ending September 30, 2018.

  • Simply Wall St.2 months ago

    Is Catalent Inc’s (NYSE:CTLT) CEO Incentives Align With Yours?

    In 2009 John Chiminski was appointed CEO of Catalent Inc (NYSE:CTLT). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Read More...

  • Associated Press2 months ago

    Catalent: Fiscal 1Q Earnings Snapshot

    The Somerset, New Jersey-based company said it had a loss of 10 cents per share. Earnings, adjusted for one-time gains and costs, came to 28 cents per share. The results missed Wall Street expectations. ...

  • Business Wire2 months ago

    Catalent, Inc. Reports First Quarter Fiscal 2019 Results

    SOMERSET, N.J.-- -- Q1'19 revenue of $551.8 million increased 1% as-reported, or 3% in constant currency, from the prior-year period. Closed the acquisition of Juniper Pharmaceuticals, a European early development Center of Excellence with dose form development and clinical manufacturing capabilities. FY'19 financial guidance reaffirmed. Catalent, Inc. , the leading global provider of advanced delivery ...

  • Business Wire3 months ago

    Catalent, Inc. to Present at Three Upcoming Investor Conferences

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, and Thomas Castellano, Vice President Finance, Investor Relations and Treasurer will present at the following conferences in the coming weeks.

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire3 months ago

    Catalent, Inc. Announces First Quarter Fiscal Year 2019 Earnings Conference Webcast

    Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2019 ended September 30, 2018, before the market open on Tuesday, November 6, 2018. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.

  • GuruFocus.com3 months ago

    Catalent Inc (CTLT) Chair, President & CEO John R Chiminski Sold $5.9 million of Shares

    Chair, President & CEO of Catalent Inc (NYSE:CTLT) John R Chiminski sold 130,545 shares of CTLT on 10/01/2018 at an average price of $45.32 a share.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CTLT earnings conference call or presentation 28-Aug-18 12:15pm GMT

    Q4 2018 Catalent Inc Earnings Call

  • New Strong Sell Stocks for September 19th
    Zacks4 months ago

    New Strong Sell Stocks for September 19th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: